Lawsuit Overview - A securities class action lawsuit has been filed against Applied Therapeutics Inc (NASDAQ: APLT) in the United States District Court for the Southern District of New York [1] - The lawsuit is on behalf of investors who purchased or acquired Applied Therapeutics securities between January 3, 2024, and December 2, 2024 [1] - The lead plaintiff deadline is February 18, 2025 [1] Allegations - The complaint alleges that Applied Therapeutics made false and/or misleading statements and/or failed to disclose that the company was not adhering to trial protocol and good clinical practices for its drug candidate, govorestat [2] - This alleged misconduct created a severe risk that the trial data would be rejected by the FDA in the context of a New Drug Application [2] Lead Plaintiff Process - Applied Therapeutics investors may seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel by February 18, 2025 [3] - The lead plaintiff is typically the investor or small group of investors with the largest financial interest who are also adequate and typical of the proposed class of investors [3] - The lead plaintiff selects counsel to represent the lead plaintiff and the class, and these attorneys, if approved by the court, are lead or class counsel [3] Law Firm Information - Kessler Topaz Meltzer & Check, LLP is prosecuting the class action and encourages Applied Therapeutics investors who have suffered significant losses to contact the firm directly [4] - The firm has a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct [4] - The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP [4]
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Applied Therapeutics, Inc.